Back to Search
Start Over
Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
- Source :
- Journal of Alzheimer's Disease
- Publication Year :
- 2021
- Publisher :
- IOS Press, 2021.
-
Abstract
- Background: The amyloid-β oligomers, consisting of 10–20 monomers (AβO10–20), have strong neurotoxicity and are associated with cognitive impairment in Alzheimer’s disease (AD). However, their role in patients with idiopathic normal pressure hydrocephalus (iNPH) is poorly understood. Objective: We hypothesized that cerebrospinal fluid (CSF) AβO10–20 accumulates in patients with iNPH, and its clearance after CSF shunting contributes to neurological improvement. We measured CSF AβO10–20 levels before and after CSF shunting in iNPH patients evaluating their diagnostic and prognostic role. Methods: We evaluated two iNPH cohorts: “evaluation” (cohort-1) with 32 patients and “validation” (cohort-2) with 13 patients. Comparison cohorts included: 27 neurologically healthy controls (HCs), and 16 AD, 15 Parkinson’s disease (PD), and 14 progressive supranuclear palsy (PSP) patients. We assessed for all cohorts CSF AβO10–20 levels and their comprehensive clinical data. iNPH cohort-1 pre-shunting data were compared with those of comparison cohorts, using cohort-2 for validation. Next, we compared cohort-1’s clinical and CSF data: 1) before and after CSF shunting, and 2) increased versus decreased AβO10–20 levels at baseline, 1 and 3 years after shunting. Results: Cohort-1 had higher CSF AβO10–20 levels than the HCs, PD, and PSP cohorts. This result was validated with data from cohort-2. CSF AβO10–20 levels differentiated cohort-1 from the PD and PSP groups, with an area under receiver operating characteristic curve of 0.94. AβO10–20 levels in cohort-1 decreased after CSF shunting. Patients with AβO10–20 decrease showed better cognitive outcome than those without. Conclusion: AβO10–20 accumulates in patients with iNPH and is eliminated by CSF shunting. AβO10–20 can be an applicable diagnostic and prognostic biomarker.
- Subjects :
- Male
0301 basic medicine
normal pressure hydrocephalus
medicine.medical_specialty
Gastroenterology
cerebrospinal fluid
Progressive supranuclear palsy
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Cerebrospinal fluid
Alzheimer Disease
Normal pressure hydrocephalus
Internal medicine
medicine
Humans
neurodegenerative diseases
In patient
Aged
Aged, 80 and over
Brain Diseases
Amyloid beta-Peptides
Amyloid-β peptides
Receiver operating characteristic
business.industry
General Neuroscience
Neurotoxicity
biomarkers
Parkinson Disease
General Medicine
medicine.disease
Cerebrospinal Fluid Shunts
Hydrocephalus, Normal Pressure
Shunting
Psychiatry and Mental health
Clinical Psychology
030104 developmental biology
(Idiopathic) normal pressure hydrocephalus
Female
Supranuclear Palsy, Progressive
Geriatrics and Gerontology
business
030217 neurology & neurosurgery
Research Article
Subjects
Details
- ISSN :
- 18758908 and 13872877
- Volume :
- 83
- Database :
- OpenAIRE
- Journal :
- Journal of Alzheimer's Disease
- Accession number :
- edsair.doi.dedup.....bd84d820913073d54b0f47907e51f9b0